Arcticzymes Technologies ASA
Arcticzymes Technologies ASA is a biotechnology company focused on the discovery and development of novel enzymes for industrial and pharmaceutical applications.
Business. Arcticzymes Technologies ASA (AZT.OL) is a pharmaceutical company operating within the Healthcare sector. The firm is headquartered in Norway and is primarily listed on the Oslo Børs. Specific details regarding its operating segments and geographic revenue mix are not available.
Analyst recommendations
2 analysts · consensus Buy- EarningsH1 2026 earnings (expected)2026-08-14 · estimated
- EarningsQ3 2026 earnings (expected)2026-11-05 · estimated
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsH1 2026 earnings (expected)2026-08-14 · estimated
- EarningsQ3 2026 earnings (expected)2026-11-05 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Arcticzymes Technologies ASA (AZT.OL) is a pharmaceutical company operating within the Healthcare sector. The firm is headquartered in Norway and is primarily listed on the Oslo Børs. Specific details regarding its operating segments and geographic revenue mix are not available.
Arcticzymes Technologies ASA maintains a strong liquidity position, with a current ratio of 16.39 and cash and equivalents amounting to NOK 187.78 million, which significantly exceeds its total liabilities of NOK 22.94 million. The company's price-to-book ratio is 3.08, and its price-to-tangible-book ratio is also 3.08, indicating a relatively high valuation relative to its book value. The company's debt-to-equity ratio is 0.02, reflecting a low level of leverage and a conservative capital structure.
In terms of profitability, Arcticzymes reported a net income of NOK 9.88 million and an operating income of NOK 2.81 million in the latest period. The return on equity (ROE) is 2.92%, and the return on assets (ROA) is 2.73%, which are relatively low compared to industry benchmarks for biotechnology firms. The company's gross profit margin is 95.8%, indicating strong cost control in production.
Arcticzymes operates in a single business segment focused on enzyme discovery and development, with no disclosed geographic revenue concentration. The company's revenue is derived from a single product line, which may pose a concentration risk if demand for its enzymes declines. The company's revenue for the latest period was NOK 112.62 million.
Looking ahead, Arcticzymes is expected to maintain a stable revenue trajectory, with no significant growth or decline projected in the next fiscal year. The company's capital expenditures were negative NOK 3.64 million, indicating a reduction in capital spending. The company's free cash flow was NOK 15.39 million, which supports its liquidity and potential for reinvestment.
The company's risk assessment indicates a low level of liquidity and dilution risk, with no immediate filing-based flags detected. The company's dilution potential is low, and no significant adjustments have been applied to its valuation metrics. The company's market price is currently NOK 20.4, and the mean price target from analysts is NOK 33.00, suggesting a potential upside.
Recent events and filings do not indicate any material changes in the company's operations or financial position. The company's operating cash flow was NOK 25.81 million, which supports its ongoing operations and financial flexibility. The company's market cap is NOK 1.04 billion, and the price-to-earnings ratio is 105.45, indicating a high valuation relative to earnings.
- Arcticzymes Technologies ASA has a strong liquidity position with a current ratio of 16.39 and significant cash reserves.
- The company's profitability metrics, including ROE and ROA, are relatively low compared to industry benchmarks.
- The company operates in a single business segment with no disclosed geographic revenue concentration, which may pose a concentration risk.
- The company's capital expenditures were negative, indicating a reduction in capital spending.
- The company's market price is currently NOK 20.4, and the mean price target from analysts is NOK 33.00, suggesting a potential upside.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 0,41 |
| Revenue | —no estimate | —no estimate | 137,0M NOK |
| Operating income | —no estimate | —no estimate | 17,5M NOK |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Ev To Operating Cash Flowenterprise_value / operating_cash_flow
- Return On Equitynet_income / total_equity
- Price To Earningsmarket_price / (net_income / shares_outstanding_diluted)
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Arcticzymes Technologies ASA Market data — financials · 2026-05-27
- Arcticzymes Technologies ASA Market data — analyst estimates · 2026-05-27
Ownership & reference
Leadership
- Michael Benjamin AkohCEO
Insider activity
Short positioning
Geographic breakdown
Intel & risk
Evidence & claims
From filings & derived data- Net margin (FY 2024-12-31): 142.6%Derived (calculated)
- Debt-to-equity (FY 2024-12-31): 0.02xDerived (calculated)
- Return on equity (FY 2024-12-31): 1.6%Derived (calculated)
- Return on assets (FY 2024-12-31): 1.6%Derived (calculated)
- Current ratio (FY 2024-12-31): 48.22xDerived (calculated)
- Net income (annual): NOK 6.76MBRREG filing
- Revenue (annual): NOK 4.74MBRREG filing
- Pre-tax income (annual): NOK 8.66MBRREG filing
- Shareholders' equity (annual): NOK 416.73MBRREG filing
- Operating income (annual): NOK -11.41MBRREG filing
- Total liabilities (annual): NOK 9.08MBRREG filing
- Current liabilities (annual): NOK 4.72MBRREG filing
- Non current liabilities (annual): NOK 4.36MBRREG filing
- Total equity & liabilities (annual): NOK 425.81MBRREG filing
- Total operating expenses (annual): NOK 16.14MBRREG filing
- Finance expense (annual): NOK 221KBRREG filing
- Total assets (annual): NOK 425.81MBRREG filing
- Non current assets (annual): NOK 198.42MBRREG filing
- Current assets (annual): NOK 227.39MBRREG filing